Pages that link to "Q39413133"
Jump to navigation
Jump to search
The following pages link to Changes in the extracellular envelope glycoprotein of variants that evolve during the course of simian immunodeficiency virus SIVMne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, (Q39413133):
Displaying 50 items.
- Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection (Q24538985) (← links)
- SIVsm quasispecies adaptation to a new simian host (Q24817181) (← links)
- Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys (Q28751926) (← links)
- Functional contributions of carbohydrate on AIDS virus glycoprotein (Q30397572) (← links)
- Animal models for HIV/AIDS research (Q30423656) (← links)
- Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways (Q33504599) (← links)
- Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen (Q33639684) (← links)
- Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines (Q33644522) (← links)
- HIV-1 Transmission, Replication Fitness and Disease Progression (Q33758570) (← links)
- Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels (Q33780649) (← links)
- Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain (Q33839044) (← links)
- Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4 (Q33851405) (← links)
- The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner (Q33883936) (← links)
- Identification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4. (Q33984371) (← links)
- Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins. (Q34010373) (← links)
- Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography (Q34027126) (← links)
- Relative replication capacity of phenotypic SIV variants during primary infections differs with route of inoculation. (Q34243486) (← links)
- Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques (Q34301728) (← links)
- Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype. (Q34349343) (← links)
- Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120. (Q34464860) (← links)
- Non-human primate models for AIDS vaccine research (Q34715769) (← links)
- Unique Pattern of Convergent Envelope Evolution in Simian Immunodeficiency Virus-Infected Rapid Progressor Macaques: Association with CD4-Independent Usage of CCR5 (Q34996824) (← links)
- Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection (Q35020053) (← links)
- Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1. (Q35076553) (← links)
- Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity (Q35101464) (← links)
- Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques (Q35636394) (← links)
- Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. (Q35857683) (← links)
- A rapid progressor-specific variant clone of simian immunodeficiency virus replicates efficiently in vivo only in the absence of immune responses (Q35947881) (← links)
- Induction of antibody-mediated neutralization in SIVmac239 by a naturally acquired V3 mutation (Q35955770) (← links)
- Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys (Q36155555) (← links)
- HIV transmission biology: translation for HIV prevention (Q36269097) (← links)
- Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus (Q36707305) (← links)
- Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo (Q36898925) (← links)
- Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies (Q36994698) (← links)
- N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies (Q37010852) (← links)
- Infection with Multiple Human Immunodeficiency Virus Type 1 Variants Is Associated with Faster Disease Progression (Q37059806) (← links)
- Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection. (Q37356028) (← links)
- A decrease in albumin in early SIV infection is related to viral pathogenicity (Q37401958) (← links)
- In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques (Q37682768) (← links)
- Role of microglial cells in selective replication of simian immunodeficiency virus genotypes in the brain (Q38886489) (← links)
- Use of helper-free replication-defective simian immunodeficiency virus-based vectors to study macrophage and T tropism: evidence for distinct levels of restriction in primary macrophages and a T-cell line (Q39137268) (← links)
- Coreceptor specificity of temporal variants of simian immunodeficiency virus Mne. (Q39137559) (← links)
- Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1. (Q39193318) (← links)
- Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1/V2-associated CD4 binding efficiency and viral entry (Q39242155) (← links)
- Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate (Q39484956) (← links)
- A Lymph Node-Derived Cytopathic Simian Immunodeficiency Virus Mne Variant Replicates in Nonstimulated Peripheral Blood Mononuclear Cells (Q39577140) (← links)
- V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies (Q39592261) (← links)
- Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. (Q39594428) (← links)
- The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors (Q39597685) (← links)
- Highly pathogenic simian immunodeficiency virus mne variants that emerge during the course of infection evolve enhanced infectivity and the ability to downregulate CD4 but not class I major histocompatibility complex antigens (Q39683959) (← links)